MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
KMDA stock logo

KMDA

Kamada Ltd.

$8.47
0
 (0%)
Exchange:  NASDAQ
Market Cap:  488.563M
Shares Outstanding:  10.611M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  Amir London
Full Time Employees:  420
Address: 
2 Holzman Street
Rehovot
7.67M
IL
Website:  https://www.kamada.com
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/14 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue142,519160,953195,342.674
Gross Profit55,49069,96778,284.285
EBITDA21,53427,80244,542.588
Operating Income10,06420,05128,396.455
Net Income8,28414,46221,863.744

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets354,907372,255378,788.617
Total Liabilities110,886112,791109,662.760
Total Stockholders Equity244,021259,464269,125.857
Total Debt8,82211,06211,563.399
Cash and Cash Equivalents55,64178,43575,484.666

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow4,31547,59427,592.179
Capital Expenditure-5,850-10,740-10,658.007
Free Cash Flow-1,53536,85416,934.172
Net Income8,414.18914,46221,863.744
Net Change in Cash21,38322,794-2,950.313

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)270,523.050Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)288,102.969Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)280,040.500Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)111,187.686Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)118,413.209Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)115,099.454Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)43,220.073Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)46,910.431Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)45,217.826Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)50,575.806Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)53,862.471Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)52,355.147Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.780Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.800Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.740Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
163.516M  ?P/S
 (TTM)
: 
2.7
?Net Income
 (TTM)
: 
14.692M  ?P/E
 (TTM)
: 
24.16
?Enterprise Value
 (TTM)
: 
425.833M  ?EV/FCF
 (TTM)
: 
26.93
?Dividend Yield
 (TTM)
: 
0.03  ?Payout Ratio
 (TTM)
: 
0.56
?ROE
 (TTM)
: 
0.08  ?ROIC
 (TTM)
: 
0.07
?Net Debt
 (TTM)
: 
-67372982.65  ?Debt/Equity
 (TTM)
: 
0.04
?P/B
 (TTM)
: 
1.82  ?Current Ratio
 (TTM)
: 
4.07

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
18.41Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates KMDA intrinsic value between $9.90 – $10.03 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate KMDA Intrinsic Value

Common questions about KMDA valuation

Is Kamada Ltd. (KMDA) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Kamada Ltd. (KMDA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is KMDA a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether KMDA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is KMDA’s P/E ratio?

You can see KMDA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for KMDA?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is KMDA a good long-term investment?

Whether KMDA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

KMDA

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0
MARKETSnap

Trading Metrics:

Open: 8.31   Previous Close: 8.47
Day Low: 8.31   Day High: 8.49
Year Low: 5.54   Year High: 9.35
Price Avg 50: 8.58   Price Avg 200: 7.53
Volume: 32116   Average Volume: 69529

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Kamada (KMDA) Q4 Earnings and Revenues Miss Estimates
11-03-2026 09:16
Kamada (KMDA) Q4 Earnings and Revenues Miss Estimates
KMDA vs. ARGX: Which Stock Is the Better Value Option?
05-03-2026 12:40
KMDA vs. ARGX: Which Stock Is the Better Value Option?
KMDA or TECH: Which Is the Better Value Stock Right Now?
17-02-2026 12:40
KMDA or TECH: Which Is the Better Value Stock Right Now?
Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock?
27-01-2026 09:25
Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock?
Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript
08-12-2025 09:26
Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript
Kamada (NASDAQ:KMDA) Share Price Passes Below 200-Day Moving Average   – Time to Sell?
03-12-2025 03:32
Kamada (NASDAQ:KMDA) Share Price Passes Below 200-Day Moving Average – Time to Sell?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read